VX-509 matching placebo

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Rheumatoid Arthritis

Phase 2

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

CompletedNCT01590459

Vertex Pharmaceuticals IncorporatedRheumatoid Arthritis

Start: 2012-04-30End: 2014-07-31Updated: 2015-11-20

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

CompletedNCT01754935

Vertex Pharmaceuticals IncorporatedRheumatoid Arthritis

Start: 2013-01-31End: 2014-02-28Updated: 2015-05-19

Related Papers

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.

2016-04-1541 citations